BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 32385563)

  • 21. Rechallenge temozolomide in glioma: A case series from India.
    Patil VM; Tonse R; Kothari R; Chandrasekaran A; Pande N; Epari S; Gupta T; Jalali R
    Indian J Cancer; 2017; 54(1):368-371. PubMed ID: 29199725
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Stereotactic irradiation in the complex treatment of patients with intracranial pilocytic astrocytoma].
    Trunin YY; Golanov AV; Konovalov AN; Pronin IN; Zagirov RI; Ryzhova MV; Kadyrov SU; Igoshina EN
    Zh Vopr Neirokhir Im N N Burdenko; 2021; 85(2):34-46. PubMed ID: 33864667
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, dehydroxymethylepoxyquinomicin.
    Starenki DV; Namba H; Saenko VA; Ohtsuru A; Maeda S; Umezawa K; Yamashita S
    Clin Cancer Res; 2004 Oct; 10(20):6821-9. PubMed ID: 15501958
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alternative lengthening of telomeres, ATRX loss and H3-K27M mutations in histologically defined pilocytic astrocytoma with anaplasia.
    Rodriguez FJ; Brosnan-Cashman JA; Allen SJ; Vizcaino MA; Giannini C; Camelo-Piragua S; Webb M; Matsushita M; Wadhwani N; Tabbarah A; Hamideh D; Jiang L; Chen L; Arvanitis LD; Alnajar HH; Barber JR; Rodríguez-Velasco A; Orr B; Heaphy CM
    Brain Pathol; 2019 Jan; 29(1):126-140. PubMed ID: 30192422
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-kappaB, as a strategy for chemoprevention and therapy of adult T-cell leukemia.
    Watanabe M; Ohsugi T; Shoda M; Ishida T; Aizawa S; Maruyama-Nagai M; Utsunomiya A; Koga S; Yamada Y; Kamihira S; Okayama A; Kikuchi H; Uozumi K; Yamaguchi K; Higashihara M; Umezawa K; Watanabe T; Horie R
    Blood; 2005 Oct; 106(7):2462-71. PubMed ID: 15956280
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A foretaste for pediatric glioblastoma therapy: targeting the NF-kB pathway with DHMEQ.
    Brassesco MS; Roberto GM; Delsin LE; Baldissera GC; Medeiros M; Umezawa K; Tone LG
    Childs Nerv Syst; 2023 Jun; 39(6):1519-1528. PubMed ID: 36807999
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Case of Therapy-Related Acute Myeloid Leukemia Associated with Adjuvant Temozolomide Chemotherapy for Anaplastic Astrocytoma.
    Kosugi K; Saito K; Takahashi W; Tokuda Y; Tomita H
    World Neurosurg; 2017 May; 101():816.e11-816.e16. PubMed ID: 28288919
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PAMs inhibits monoamine oxidase a activity and reduces glioma tumor growth, a potential adjuvant treatment for glioma.
    Li PC; Chen SY; Xiangfei D; Mao C; Wu CH; Shih JC
    BMC Complement Med Ther; 2020 Aug; 20(1):252. PubMed ID: 32799864
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemotherapy for pilocytic astrocytomas.
    Brown MT; Friedman HS; Oakes WJ; Boyko OB; Hockenberger B; Schold SC
    Cancer; 1993 May; 71(10):3165-72. PubMed ID: 8490847
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.
    McDuff SGR; Dietrich J; Atkins KM; Oh KS; Loeffler JS; Shih HA
    Cancer Med; 2020 Jan; 9(1):3-11. PubMed ID: 31701682
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antitumor effects of dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, in human liver cancer cells are mediated through a reactive oxygen species-dependent mechanism.
    Lampiasi N; Azzolina A; D'Alessandro N; Umezawa K; McCubrey JA; Montalto G; Cervello M
    Mol Pharmacol; 2009 Aug; 76(2):290-300. PubMed ID: 19461054
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    Wu L; Bernal GM; Cahill KE; Pytel P; Fitzpatrick CA; Mashek H; Weichselbaum RR; Yamini B
    Sci Transl Med; 2018 Jul; 10(448):. PubMed ID: 29973405
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Present and potential future adjuvant issues in high-grade astrocytic glioma treatment.
    Lefranc F; Rynkowski M; DeWitte O; Kiss R
    Adv Tech Stand Neurosurg; 2009; 34():3-35. PubMed ID: 19368079
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trametinib for progressive pediatric low-grade gliomas.
    Kondyli M; Larouche V; Saint-Martin C; Ellezam B; Pouliot L; Sinnett D; Legault G; Crevier L; Weil A; Farmer JP; Jabado N; Perreault S
    J Neurooncol; 2018 Nov; 140(2):435-444. PubMed ID: 30097824
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of cathepsin L sensitizes human glioma cells to ionizing radiation in vitro through NF-κB signaling pathway.
    Yang N; Wang P; Wang WJ; Song YZ; Liang ZQ
    Acta Pharmacol Sin; 2015 Mar; 36(3):400-10. PubMed ID: 25661319
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose-dependent biphasic induction and transcriptional activity of nuclear factor kappa B (NF-kappaB) in EA.hy.926 endothelial cells after low-dose X-irradiation.
    Rödel F; Hantschel M; Hildebrandt G; Schultze-Mosgau S; Rödel C; Herrmann M; Sauer R; Voll RE
    Int J Radiat Biol; 2004 Feb; 80(2):115-23. PubMed ID: 15164793
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dehydroxymethylepoxyquinomicin, a novel nuclear factor-κB inhibitor, reduces chemokines and adhesion molecule expression induced by IL-1β in human corneal fibroblasts.
    Inokawa S; Watanabe T; Keino H; Sato Y; Hirakata A; Okada AA; Fukuda K; Fukushima A; Umezawa K
    Graefes Arch Clin Exp Ophthalmol; 2015 Apr; 253(4):557-63. PubMed ID: 25519802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reversal of resistance to cytotoxic cancer therapies: DHMEQ as a chemo-sensitizing and immuno-sensitizing agent.
    Katsman A; Umezawa K; Bonavida B
    Drug Resist Updat; 2007; 10(1-2):1-12. PubMed ID: 17306602
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
    Boccard SG; Marand SV; Geraci S; Pycroft L; Berger FR; Pelletier LA
    Oncotarget; 2015 Oct; 6(30):29456-68. PubMed ID: 26336131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.